We have read with great interest the papers by Ibrahim et al1 and Hamblin et al2 regarding conversion of CD38 expression and prognosis of B-CLL. The former described how one of their B-CLL patients showed a change of CD38 expression level from low (< 30%) to high (≥ 30%), with significant worsening in the patient's clinical condition. The latter investigators also reported changes in CD38 expression over time in 10 of 41 CLL patients. Of these 10 patients, 2 showed a conversion from low to high levels of CD38 expression. However, the authors concluded that this conversion was not definitely associated with changes in clinical course.

Here, we describe 3 B-CLL patients who showed a conversion of CD38 expression (case #1, Table 1), CD13 expression (case #2, Table 1), or CD38 and CD15 expression (case #3, Table 1) from low level to high level during follow-up. The expression of these markers was evaluated by multicolor flow cytometry using fresh bone marrow samples. The low level or high level of expression of each marker was defined using 30% as the cutoff value as reported by previous studies.1-4 This conversion occurred at about 15, 8, and 12 years after diagnosis, respectively, and appeared to be associated with a change in clinical course from indolent to aggressive. These patients died with disease 21 months (case #1), 7 months (case #2), and 3 years (case #3) following this conversion. Of the 3 patients, 2 (cases #2 and #3) also required chemotherapy after conversion. Additionally, there was no evidence of morphologic transformation in the neoplastic cells during this conversion. Thus, the change of surface marker expression status was the only detectable sign for the conversion of clinical course. Previous studies by others and us have suggested that expression of myeloid-associated markers such as CD13, CD14, CD11c, or CD11b on neoplastic lymphocytes in B-CLL correlate with an unfavorable prognosis.5-10 The change of expression of myeloid-associated markers from low to high level and the possible relationship with clinical progression has not been described previously, to our knowledge.

Table 1.

Levels of CD38 and/or myeloid-associated marker expression over the course of disease in 3 B-CLL patients

Case #1    
 Month* 178 182 203 
 CD38 level 20% 38% 57% 
Case #2    
 Month 93 94 96 
 CD13 level 2% 0% 50% 
Case 3    
 Month 136 147 NA 
 CD38 level 21% 48% NA 
 CD15 level 13% 38% NA 
Case #1    
 Month* 178 182 203 
 CD38 level 20% 38% 57% 
Case #2    
 Month 93 94 96 
 CD13 level 2% 0% 50% 
Case 3    
 Month 136 147 NA 
 CD38 level 21% 48% NA 
 CD15 level 13% 38% NA 
*

Months after initial diagnosis.

The time and levels at marker conversion.

NA indicates not applicable.

Whether the levels of CD38 expression change over the course of B-CLL remains controversial. In contrast to the studies cited above, Damle et al have reported that levels of CD38 expression do not show significant change during follow-up among the B-CLL patients they studied.4 Stable CD38 expression again was noted in another recent study by Durig et al.3 The cause of this discrepancy among different studies is unclear but may be due to the differences in the length of follow-up of the patients studied, since the conversion may occur very late in the clinical course (15 years in case #1.)

In summary, the findings in our cases suggest that levels of CD38 and myeloid-associated marker expression can change over the course of disease in B-CLL patients and support the observations by Ibrahim et al1 and Hamblin et al.2 Furthermore, the conversion from low- to high-level expression of these markers may be associated with a change from an indolent to an aggressive clinical course as observed by Ibrahim et al.1 Periodic monitoring of CD38 and, possibly, myeloid-associated markers may be necessary to fully assess the clinical/prognostic status of B-CLL patients. Also, as noted by others, additional studies are necessary to determine the most appropriate prognostic markers and methods for monitoring these patients.

1
Ibrahim
S
Keating
M
Do KA
et al
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.
Blood.
98
2001
181
186
2
Hamblin
TJ
Orchard
JA
Ibbotson
RE
et al
CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.
Blood.
99
2002
1023
1029
3
Durig
J
Naschar
M
Schmucker
U
et al
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.
Leukemia.
16
2002
30
35
4
Damle
RN
Wasil
T
Fais
F
et al
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Blood.
94
1999
1840
1847
5
Liu
YC
Cleveland
RP
Madelaire
C
Hines
JD
Discordant immunophenotype of chronic B-cell lymphoproliferative disorders in simultaneous specimens from bone marrow and peripheral sites.
Arch Pathol Lab Med.
119
1995
53
58
6
Pinto
A
Del Vecchio
L
Carbone
A
et al
Expression of myelomonocytic antigens is associated with unfavourable clinicoprognostic factors in B-cell chronic lymphocytic leukaemia.
Ann Oncol.
2(suppl 2)
1991
107
113
7
Molica
S
Myelomonocytic associated antigens in early B-chronic lymphocytic leukemia correlate with disease activity.
Am J Hematol.
40
1992
319
320
8
Pinto
A
Del Vecchio
L
Expression of myelomonocytic antigens on chronic lymphocytic leukemia B cells.
Blood.
72
1988
1438
9
Tassies
D
Montserrat
E
Reverter
JC
Villamor
N
Rovira
M
Rozman
C
Myelomonocytic antigens in B-cell chronic lymphocytic leukemia.
Leuk Res.
19
1995
841
848
10
Callea
V
Morabito
F
Oliva
BM
et al
Surface CD14 positivity in B-cell chronic lymphocytic leukaemia is related to clinical outcome.
Br J Haematol.
107
1999
347
352
Sign in via your Institution